Radiation	O
therapy	O
dose	O
is	O
associated	O
with	O
improved	O
survival	O
for	O
unresected	B:C2986425
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
:	O
Outcomes	O
from	O
the	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
.	O

Radiation	O
therapy	O
dose	O
is	O
associated	O
with	O
improved	O
survival	O
for	O
unresected	O
anaplastic	B:C0238461
thyroid	I:C0238461
carcinoma	I:C0238461
:	O
Outcomes	O
from	O
the	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
.	O

Radiation	O
therapy	O
dose	O
is	O
associated	O
with	O
improved	O
survival	O
for	O
unresected	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
:	O
Outcomes	O
from	O
the	O
National	B:C0242356
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
.	O

The	O
outcomes	O
of	O
patients	O
with	O
unresected	B:C2986425
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
(	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
)	O
from	O
the	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
(	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
)	O
were	O
assessed	O
,	O
and	O
potential	O
correlations	O
were	O
explored	O
between	O
radiation	O
therapy	O
(	O
RT	O
)	O
dose	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
outcomes	O
of	O
patients	O
with	O
unresected	O
anaplastic	B:C0238461
thyroid	I:C0238461
carcinoma	I:C0238461
(	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
)	O
from	O
the	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
(	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
)	O
were	O
assessed	O
,	O
and	O
potential	O
correlations	O
were	O
explored	O
between	O
radiation	O
therapy	O
(	O
RT	O
)	O
dose	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
outcomes	O
of	O
patients	O
with	O
unresected	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
(	O
anaplastic	B:C0238461
thyroid	I:C0238461
carcinoma	I:C0238461
)	O
from	O
the	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
(	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
)	O
were	O
assessed	O
,	O
and	O
potential	O
correlations	O
were	O
explored	O
between	O
radiation	O
therapy	O
(	O
RT	O
)	O
dose	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
outcomes	O
of	O
patients	O
with	O
unresected	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
(	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
)	O
from	O
the	O
National	B:C0242356
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
(	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
)	O
were	O
assessed	O
,	O
and	O
potential	O
correlations	O
were	O
explored	O
between	O
radiation	O
therapy	O
(	O
RT	O
)	O
dose	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
outcomes	O
of	O
patients	O
with	O
unresected	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
(	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
)	O
from	O
the	O
National	O
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
(	O
National	B:C0242356
Cancer	I:C0242356
Data	I:C0242356
Base	I:C0242356
)	O
were	O
assessed	O
,	O
and	O
potential	O
correlations	O
were	O
explored	O
between	O
radiation	O
therapy	O
(	O
RT	O
)	O
dose	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
study	O
cohort	O
was	O
comprised	O
of	O
patients	O
who	O
underwent	O
either	O
no	O
surgery	O
or	O
grossly	O
incomplete	O
resection	B:C0728940
.	O

The	O
mean	O
patient	O
age	O
was	O
70.2	O
years	O
,	O
59.7	O
%	O
of	O
patients	O
were	O
women	B:C0043210
,	O
and	O
47.6	O
%	O
received	O
neck	O
RT	I:C1997944
.	O

The	O
mean	O
patient	O
age	O
was	O
70.2	O
years	O
,	O
59.7	O
%	O
of	O
patients	O
were	O
women	O
,	O
and	O
47.6	O
%	O
received	O
neck	B:C1997944
RT	I:C1997944
.	O

The	O
median	O
OS	O
was	O
2.27	O
months	O
,	O
and	O
11	O
%	O
of	O
patients	O
remained	O
alive	B:C2584946
at	O
1	O
year	O
.	O

A	O
positive	O
RT	O
dose	O
-	O
survival	O
correlation	O
was	O
observed	O
for	O
the	O
entire	O
study	O
cohort	O
,	O
for	O
those	O
who	O
received	O
systemic	B:C1515119
therapy	I:C1515119
,	O
and	O
for	O
those	O
with	O
stage	O
IVA	I:C0456600
/	O
IVB	O
and	O
IVC	O
disease	O
.	O

A	O
positive	O
RT	O
dose	O
-	O
survival	O
correlation	O
was	O
observed	O
for	O
the	O
entire	O
study	O
cohort	O
,	O
for	O
those	O
who	O
received	O
systemic	O
therapy	I:C1515119
,	O
and	O
for	O
those	O
with	O
stage	B:C0456600
IVA	I:C0456600
/	O
IVB	O
and	O
IVC	O
disease	O
.	O

A	O
positive	O
RT	O
dose	O
-	O
survival	O
correlation	O
was	O
observed	O
for	O
the	O
entire	O
study	O
cohort	O
,	O
for	O
those	O
who	O
received	O
systemic	O
therapy	I:C1515119
,	O
and	O
for	O
those	O
with	O
stage	O
IVA	I:C0456600
/	O
IVB	B:C0456601
and	O
IVC	O
disease	O
.	O

A	O
positive	O
RT	O
dose	O
-	O
survival	O
correlation	O
was	O
observed	O
for	O
the	O
entire	O
study	O
cohort	O
,	O
for	O
those	O
who	O
received	O
systemic	O
therapy	I:C1515119
,	O
and	O
for	O
those	O
with	O
stage	O
IVA	I:C0456600
/	O
IVB	O
and	O
IVC	B:C0441774
disease	O
.	O

On	O
MVA	O
,	O
older	B:C1999167
age	I:C1999167
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.317	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.137-1.526	O
)	O
,	O
�€‰�‰��€	O
‰1	O
comorbidity	O
(	O
HR	O
,	O
1.587	O
;	O
95	O
%	O
CI	O
,	O
1.379-1.827	O
)	O
,	O
distant	O
metastasis	I:C1302548
(	O
HR	O
,	O
1.385	O
;	O
95	O
%	O
CI	O
,	O
1.216-1.578	O
)	O
,	O
receipt	O
of	O
systemic	O
therapy	I:C1515119
(	O
HR	O
,	O
0.637	O
;	O
95	O
%	O
CI	O
,	O
0.547-0.742	O
)	O
,	O
and	O
receipt	O
of	O
radiation	O
therapy	I:C0034619
compared	O
with	O
no	O
RT	O
(	O
<	O
45	O
grays	O
[	O
Gy	O
]	O
:	O
HR	O
,	O
0.843	O
;	O
95	O
%	O
CI	O
,	O
0.718-0.988	O
;	O
45-59.9	O
Gy	O
:	O
HR	O
,	O
0.596	O
;	O
95	O
%	O
CI	O
,	O
0.479-0.743	O
;	O
60-75	O
Gy	O
:	O
HR	O
,	O
0.419	O
;	O
95	O
%	O
CI	O
,	O
0.339-0.517	O
)	O
correlated	O
with	O
OS	O
.	O

On	O
MVA	O
,	O
older	O
age	I:C1999167
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.317	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.137-1.526	O
)	O
,	O
�€‰�‰��€	O
‰1	O
comorbidity	O
(	O
HR	O
,	O
1.587	O
;	O
95	O
%	O
CI	O
,	O
1.379-1.827	O
)	O
,	O
distant	B:C1302548
metastasis	I:C1302548
(	O
HR	O
,	O
1.385	O
;	O
95	O
%	O
CI	O
,	O
1.216-1.578	O
)	O
,	O
receipt	O
of	O
systemic	O
therapy	I:C1515119
(	O
HR	O
,	O
0.637	O
;	O
95	O
%	O
CI	O
,	O
0.547-0.742	O
)	O
,	O
and	O
receipt	O
of	O
radiation	O
therapy	I:C0034619
compared	O
with	O
no	O
RT	O
(	O
<	O
45	O
grays	O
[	O
Gy	O
]	O
:	O
HR	O
,	O
0.843	O
;	O
95	O
%	O
CI	O
,	O
0.718-0.988	O
;	O
45-59.9	O
Gy	O
:	O
HR	O
,	O
0.596	O
;	O
95	O
%	O
CI	O
,	O
0.479-0.743	O
;	O
60-75	O
Gy	O
:	O
HR	O
,	O
0.419	O
;	O
95	O
%	O
CI	O
,	O
0.339-0.517	O
)	O
correlated	O
with	O
OS	O
.	O

On	O
MVA	O
,	O
older	O
age	I:C1999167
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.317	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.137-1.526	O
)	O
,	O
�€‰�‰��€	O
‰1	O
comorbidity	O
(	O
HR	O
,	O
1.587	O
;	O
95	O
%	O
CI	O
,	O
1.379-1.827	O
)	O
,	O
distant	O
metastasis	I:C1302548
(	O
HR	O
,	O
1.385	O
;	O
95	O
%	O
CI	O
,	O
1.216-1.578	O
)	O
,	O
receipt	O
of	O
systemic	B:C1515119
therapy	I:C1515119
(	O
HR	O
,	O
0.637	O
;	O
95	O
%	O
CI	O
,	O
0.547-0.742	O
)	O
,	O
and	O
receipt	O
of	O
radiation	O
therapy	I:C0034619
compared	O
with	O
no	O
RT	O
(	O
<	O
45	O
grays	O
[	O
Gy	O
]	O
:	O
HR	O
,	O
0.843	O
;	O
95	O
%	O
CI	O
,	O
0.718-0.988	O
;	O
45-59.9	O
Gy	O
:	O
HR	O
,	O
0.596	O
;	O
95	O
%	O
CI	O
,	O
0.479-0.743	O
;	O
60-75	O
Gy	O
:	O
HR	O
,	O
0.419	O
;	O
95	O
%	O
CI	O
,	O
0.339-0.517	O
)	O
correlated	O
with	O
OS	O
.	O

On	O
MVA	O
,	O
older	O
age	I:C1999167
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.317	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.137-1.526	O
)	O
,	O
�€‰�‰��€	O
‰1	O
comorbidity	O
(	O
HR	O
,	O
1.587	O
;	O
95	O
%	O
CI	O
,	O
1.379-1.827	O
)	O
,	O
distant	O
metastasis	I:C1302548
(	O
HR	O
,	O
1.385	O
;	O
95	O
%	O
CI	O
,	O
1.216-1.578	O
)	O
,	O
receipt	O
of	O
systemic	O
therapy	I:C1515119
(	O
HR	O
,	O
0.637	O
;	O
95	O
%	O
CI	O
,	O
0.547-0.742	O
)	O
,	O
and	O
receipt	O
of	O
radiation	B:C0034619
therapy	I:C0034619
compared	O
with	O
no	O
RT	O
(	O
<	O
45	O
grays	O
[	O
Gy	O
]	O
:	O
HR	O
,	O
0.843	O
;	O
95	O
%	O
CI	O
,	O
0.718-0.988	O
;	O
45-59.9	O
Gy	O
:	O
HR	O
,	O
0.596	O
;	O
95	O
%	O
CI	O
,	O
0.479-0.743	O
;	O
60-75	O
Gy	O
:	O
HR	O
,	O
0.419	O
;	O
95	O
%	O
CI	O
,	O
0.339-0.517	O
)	O
correlated	O
with	O
OS	O
.	O

Survival	O
was	O
poor	O
in	O
this	O
cohort	B:C0599755
of	O
patients	O
with	O
unresected	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
,	O
and	O
more	O
effective	O
therapies	O
are	O
needed	O
.	O

Survival	O
was	O
poor	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
unresected	B:C2986425
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
,	O
and	O
more	O
effective	O
therapies	O
are	O
needed	O
.	O

Survival	O
was	O
poor	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
unresected	O
anaplastic	B:C0238461
thyroid	I:C0238461
carcinoma	I:C0238461
,	O
and	O
more	O
effective	O
therapies	O
are	O
needed	O
.	O

Survival	O
was	O
poor	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
unresected	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
,	O
and	O
more	O
effective	O
therapies	B:C0087111
are	O
needed	O
.	O

However	O
,	O
the	O
association	O
of	O
RT	O
dose	O
with	O
OS	O
highlights	O
the	O
importance	O
of	O
identifying	B:C1269815
patients	I:C1269815
with	O
unresected	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
who	O
may	O
still	O
yet	O
benefit	O
from	O
multimodal	O
locoregional	I:C0009429
treatment	I:C0009429
that	O
incorporates	O
higher	O
dose	O
RT	O
.	O

However	O
,	O
the	O
association	O
of	O
RT	O
dose	O
with	O
OS	O
highlights	O
the	O
importance	O
of	O
identifying	O
patients	I:C1269815
with	O
unresected	B:C2986425
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
who	O
may	O
still	O
yet	O
benefit	O
from	O
multimodal	O
locoregional	I:C0009429
treatment	I:C0009429
that	O
incorporates	O
higher	O
dose	O
RT	O
.	O

However	O
,	O
the	O
association	O
of	O
RT	O
dose	O
with	O
OS	O
highlights	O
the	O
importance	O
of	O
identifying	O
patients	I:C1269815
with	O
unresected	O
anaplastic	B:C0238461
thyroid	I:C0238461
carcinoma	I:C0238461
who	O
may	O
still	O
yet	O
benefit	O
from	O
multimodal	O
locoregional	I:C0009429
treatment	I:C0009429
that	O
incorporates	O
higher	O
dose	O
RT	O
.	O

However	O
,	O
the	O
association	O
of	O
RT	O
dose	O
with	O
OS	O
highlights	O
the	O
importance	O
of	O
identifying	O
patients	I:C1269815
with	O
unresected	O
anaplastic	O
thyroid	I:C0238461
carcinoma	I:C0238461
who	O
may	O
still	O
yet	O
benefit	O
from	O
multimodal	B:C0009429
locoregional	I:C0009429
treatment	I:C0009429
that	O
incorporates	O
higher	O
dose	O
RT	O
.	O

